Rothblatt Martine A sold 494 shares of UNITED THERAPEUTICS Corp at $583.80 for −$288k on Nov 9, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chairperson & CEO
Chairperson & CEO
Filed Nov 10, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$288,397.55Shares × reported price
Shares traded
494Common Stock
Price per share
$583.80Reported price. Read footnotes for ranges.
% of reported position traded
0.15%This security and ownership context
Holdings after
325,563Indirect · by Trust
Trade date
Nov 9, 2026Sell
Filed
Nov 10, 2026, 4:35 PM ET1-day reporting delay
Accession
0001106578-26-000185Code S · Transaction 397180
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 326,057 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell840$584.70−$491,148.08Trade 397181
Nov 9, 2026Sell280$585.63−$163,975.22Trade 397182
3 transaction rows in this filing. Joint filers share the same rows.

UTHR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
UTHR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −6.7%1w ago +1.3%1d ago −4.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: This transaction was executed in multiple trades at prices ranging from $583.21 to $584.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. F4: This transaction was executed in multiple trades at prices ranging from $584.24 to $585.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5: This transaction was executed in multiple trades at prices ranging from $585.39 to $586.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. F7: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. F8: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.